Fidelity Investments
INO icon

Fidelity Investments’s Inovio Pharmaceuticals INO Stock Holding History

Fidelity Investments’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.3M Sell
9,339,614
-507,050
-5% -$835K ﹤0.01% 1856
2025
Q4 		$17.1M Buy
9,846,664
+9,845,363
+756,753% +$21.7M ﹤0.01% 1833
2025
Q3 		$3.04K Sell
1,301
-86,043
-99% -$165K ﹤0.01% 4878
2025
Q2 		$178K Sell
87,344
-13,331
-13% -$25.5K ﹤0.01% 3352
2025
Q1 		$164K Buy
100,675
+19,295
+24% +$38.7K ﹤0.01% 3331
2024
Q4 		$149K Buy
81,380
+54,119
+199% +$240K ﹤0.01% 3385
2024
Q3 		$158K Buy
27,261
+21,462
+370% +$177K ﹤0.01% 3283
2024
Q2 		$46.9K Sell
5,799
-6,612
-53% -$69.6K ﹤0.01% 3650
2024
Q1 		$172K Buy
12,411
+237
+2% +$2.05K ﹤0.01% 3083
2023
Q4 		$74.5K Sell
12,174
-3,271
-21% -$16.1K ﹤0.01% 3337
2023
Q3 		$72.1K Buy
15,445
+13,336
+632% +$73.7K ﹤0.01% 3217
2023
Q2 		$11.3K Buy
2,109
+1,390
+193% +$11.2K ﹤0.01% 4105
2023
Q1 		$7.08K Sell
719
-565
-44% -$9.63K ﹤0.01% 4262
2022
Q4 		$24K Sell
1,284
-86
-6% -$1.95K ﹤0.01% 3717
2022
Q3 		$28K Buy
1,370
+848
+162% +$21.7K ﹤0.01% 3708
2022
Q2 		$11K Buy
522
+202
+63% +$5.69K ﹤0.01% 4086
2022
Q1 		$14K Buy
320
+314
+5,233% +$14.1K ﹤0.01% 4130
2021
Q4 		$0 Sell
6
-55
-90% -$4.41K ﹤0.01% 4657
2021
Q3 		$5K Buy
61
+24
+65% +$2.41K ﹤0.01% 3799
2021
Q2 		$4K Buy
37
+27
+270% +$2.59K ﹤0.01% 3782
2021
Q1 		$1K Sell
10
-22,911
-100% -$3.01M ﹤0.01% 3843
2020
Q4 		$2.43M Sell
22,921
-41,296
-64% -$5.5M ﹤0.01% 2366
2020
Q3 		$8.94M Buy
64,217
+63,630
+10,840% +$13.3M ﹤0.01% 1869
2020
Q2 		$190K Buy
+587
New +$94.3K ﹤0.01% 2638
2018
Q4 		– Sell
-33,292
Closed -$2.22M – 3828
2018
Q3 		$2.22M Buy
+33,292
New +$1.85M ﹤0.01% 2346

Other funds holding INO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments's INO Position: Q1 2026 in Review

Fidelity Investments reduced its Inovio Pharmaceuticals (INO) stake by 5.1% in Q1 2026, selling an estimated $835K and leaving 9,339,614 shares worth $16.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1856.

Fidelity Investments first reported a position in INO in Q3 2018 and has held it in 25 quarters since. The position peaked at $17.1M in Q4 2025. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

  • Fidelity Investments held 9,339,614 shares of Inovio Pharmaceuticals worth $16.3M as of Q1 2026.
  • Fidelity Investments sold 507,050 Inovio Pharmaceuticals shares in Q1 2026, an estimated $835K.
  • Inovio Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #1856 holding.
  • Fidelity Investments first reported a position in Inovio Pharmaceuticals in Q3 2018 and has held it in 25 quarters since.
  • Fidelity Investments's Inovio Pharmaceuticals position peaked at $17.1M in Q4 2025.
  • 100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.